The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MGX | +64.06% | N/A | N/A | -69% |
| S&P | +15.06% | +95.03% | +14.29% | +34% |
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.51M | -57.5% |
| Gross Profit | $7.18M | -61.6% |
| Gross Margin | 84.32% | -9.1% |
| Market Cap | $55.32M | -63.8% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 171 | 0.0% |
| Net Income | -$19.91M | -85.4% |
| EBITDA | -$19.65M | -26.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.85M | -56.1% |
| Accounts Receivable | $0.87M | -47.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $37.48M | -11.9% |
| Short Term Debt | $5.51M | 2.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.47% | 0.0% |
| Return On Invested Capital | -23.25% | -1.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.38M | 20.7% |
| Operating Free Cash Flow | -$21.25M | 19.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.30 | 0.53 | 0.22 | 0.26 | -53.08% |
| Price to Sales | 1.45 | 2.58 | 1.11 | 1.63 | -40.41% |
| Price to Tangible Book Value | 0.30 | 0.53 | 0.22 | 0.26 | -53.08% |
| Enterprise Value to EBITDA | 7.08 | 3.52 | 4.96 | 5.45 | -14.57% |
| Return on Equity | -30.3% | -34.7% | -31.9% | -37.4% | 33.56% |
| Total Debt | $46.07M | $45.78M | $44.44M | $42.99M | -10.33% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
